| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
JAZZ Technical Analysis
5
| As on 9th Jun 2023 JAZZ SHARE Price closed @ 127.10 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 147.82 & Strong Sell for SHORT-TERM with Stoploss of 137.76 we also expect STOCK to react on Following IMPORTANT LEVELS. |
JAZZSHARE Price
| Open | 127.29 | Change | Price | % |
| High | 128.70 | 1 Day | -0.49 | -0.38 |
| Low | 126.59 | 1 Week | 1.20 | 0.95 |
| Close | 127.10 | 1 Month | -14.08 | -9.97 |
| Volume | 420387 | 1 Year | 1.81 | 1.44 |
| 52 Week High 168.66 | 52 Week Low 124.53 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| JAZZ Daily Charts |
JAZZ Intraday Charts |
Whats New @ Bazaartrend |
JAZZ Free Analysis |
|
|
JAZZ Important Levels Intraday
| RESISTANCE | 131.17 |
| RESISTANCE | 129.86 |
| RESISTANCE | 129.06 |
| RESISTANCE | 128.25 |
| SUPPORT | 125.95 |
| SUPPORT | 125.14 |
| SUPPORT | 124.34 |
| SUPPORT | 123.03 |
JAZZ Forecast April 2024
| 4th UP Forecast | 170.25 |
| 3rd UP Forecast | 156.41 |
| 2nd UP Forecast | 147.86 |
| 1st UP Forecast | 139.3 |
| 1st DOWN Forecast | 114.9 |
| 2nd DOWN Forecast | 106.34 |
| 3rd DOWN Forecast | 97.79 |
| 4th DOWN Forecast | 83.95 |
JAZZ Weekly Forecast
| 4th UP Forecast | 140.15 |
| 3rd UP Forecast | 135.96 |
| 2nd UP Forecast | 133.38 |
| 1st UP Forecast | 130.79 |
| 1st DOWN Forecast | 123.41 |
| 2nd DOWN Forecast | 120.82 |
| 3rd DOWN Forecast | 118.24 |
| 4th DOWN Forecast | 114.05 |
JAZZ Forecast2024
| 4th UP Forecast | 217.78 |
| 3rd UP Forecast | 188.7 |
| 2nd UP Forecast | 170.72 |
| 1st UP Forecast | 152.75 |
| 1st DOWN Forecast | 101.45 |
| 2nd DOWN Forecast | 83.48 |
| 3rd DOWN Forecast | 65.5 |
| 4th DOWN Forecast | 36.42 |
Jazz Pharmaceuticals plc ( NASDAQ USA Symbol : JAZZ )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
JAZZ Business Profile
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP-385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP-458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP-150 for treatment of post-traumatic stress disorder. Jazz Pharmaceuticals plc has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc . The company was founded in 2003 and is headquartered in Dublin, Ireland. Address: Waterloo Exchange, Dublin, Ireland, 4
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service